IR-Med
Rosh Pinna, Israel· Est.
Infrared‑AI platform delivering non‑invasive, point‑of‑care diagnostics for wounds, infections and drug monitoring.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Infrared‑AI platform delivering non‑invasive, point‑of‑care diagnostics for wounds, infections and drug monitoring.
Wound CareDiabetesInfectious DiseasePharmacology
Technology Platform
Infrared spectroscopy combined with proprietary AI algorithms to non‑invasively profile biomarkers from blood and tissue for real‑time point‑of‑care decision support.
Opportunities
Regulatory clearance and commercial launch of PressureSafe could unlock a multi‑billion‑dollar wound‑care diagnostics market, while the platform’s modularity enables rapid expansion into drug monitoring and infectious disease diagnostics.
Risk Factors
Regulatory approval timelines, reimbursement uncertainty, and competition from established POC diagnostic manufacturers could delay market entry and revenue generation.
Competitive Landscape
IR-Med competes with other non‑invasive spectroscopy and AI‑driven diagnostic firms, but differentiates itself through skin‑tone‑agnostic performance and a unified platform that can address multiple indications.